Interest grows in 3 experimental Covid treatments - ISRAEL21c

In February, the world’s attention was focused on Covid-19 experimental drugs. By April, with the worldwide vaccine campaign in full swing, Covid treatments didn’t seem important anymore.

Now that we k away despite vaccines, Covid drugs are back on the front burner.

In February, the world’s attention was focused on Covid-19 experimental drugs. By April, with the worldwide vaccine campaign in full swing, Covid treatments didn’t seem important anymore.

Now that we know the virus isn’t going away despite vaccines, Covid drugs are back on the front burner.

“Just two months ago, interest in Covid therapeutics was done. Everyone thought it was over because the vaccines were working well. And then Delta came along,” says Shai Novik, executive chairman of Enlivex Therapeutics.
Novik says that the large number of unvaccinated people in the world “creates a playing field for mutations,” currently the Delta (Indian) and Delta-plus variants.

That means there’s an urgent need for “a slew of therapeutics for mild, moderate, severe and critical cases of Covid-19,” he tells ISRAEL21c, explaining that not every patient responds the same, and different levels of illness require different drugs or drug combinations.

Here we report on the progress of three promising Israeli drug candidates for treating Covid-19. One is given intravenously; one is swallowed as a pill; and one is inhaled.